

Actinium Pharmaceuticals, Inc.
 Form 4
 July 05, 2016

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Memorial Sloan-Kettering Cancer Center

2. Issuer Name and Ticker or Trading Symbol
 Actinium Pharmaceuticals, Inc.
 [ATNM]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
 1275 YORK AVE.
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)
 06/30/2016

____ Director
 ____ Officer (give title below)
 10% Owner
 ____ Other (specify below)

NEW YORK, NY 10065

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 ____ Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)		
				Code	V	Amount				(A) or (D)	Price
Common Stock	06/30/2016		S			15,200	D	\$ 1.8	5,140,786	D	
Common Stock	06/30/2016		S			300	D	\$ 1.8025	5,140,486	D	
Common Stock	06/30/2016		S			300	D	\$ 1.805	5,140,186	D	
Common Stock	06/30/2016		S			3,350	D	\$ 1.82	5,136,836	D	
Common Stock	07/01/2016		S			44,841	D	\$ 1.8	5,091,995	D	

Edgar Filing: Actinium Pharmaceuticals, Inc. - Form 4

Common Stock	07/01/2016	S	3,200	D	\$ 1.8001	5,088,795	D
Common Stock	07/01/2016	S	200	D	\$ 1.8015	5,088,595	D
Common Stock	07/01/2016	S	100	D	\$ 1.8025	5,088,495	D
Common Stock	07/01/2016	S	11,350	D	\$ 1.805	5,077,145	D
Common Stock	07/01/2016	S	25,800	D	\$ 1.81	5,051,345	D
Common Stock	07/01/2016	S	7,362	D	\$ 1.8101	5,043,983	D
Common Stock	07/01/2016	S	200	D	\$ 1.8115	5,043,793	D
Common Stock	07/01/2016	S	4,300	D	\$ 1.815	5,039,483	D
Common Stock	07/01/2016	S	13,830	D	\$ 1.82	5,025,653	D
Common Stock	07/01/2016	S	1,400	D	\$ 1.825	5,024,253	D
Common Stock	07/01/2016	S	700	D	\$ 1.83	5,023,553	D
Common Stock	07/01/2016	S	3,617	D	\$ 1.85	5,019,936	D
Common Stock	07/01/2016	S	100	D	\$ 1.855	5,019,836	D
Common Stock	07/01/2016	S	5,900	D	\$ 1.86	5,013,936	D
Common Stock	07/01/2016	S	1,400	D	\$ 1.865	5,012,536	D
Common Stock	07/01/2016	S	1,700	D	\$ 1.87	5,010,836	D
Common Stock	07/01/2016	S	2,550	D	\$ 1.88	5,008,286	D
Common Stock	07/01/2016	S	100	D	\$ 1.9	5,008,186	D
Common Stock	07/01/2016	S	300	D	\$ 1.91	5,007,886	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not

SEC 1474
(9-02)

required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Following Transaction (Instr. 5)
--	--	--------------------------------------	--	--------------------------------	---	--	---	--	---

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Memorial Sloan-Kettering Cancer Center 1275 YORK AVE. NEW YORK, NY 10065		X		

Signatures

/s/ Memorial Sloan-Kettering Cancer Center, By Mark Svenningson, its Sr. Vice President
Finance and Controller

07/05/2016

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.